Laboratorios Farmaceuticos Rovi SA 2017 AR2
The report highlights Laboratorios Farmaceuticos ROVI's financial and ESG performance for the fiscal year 2017, marked by a 4% growth in operating revenue to 275.6 million euros. Key achievements include the international launch of its enoxaparin biosimilar in Germany and the commencement of the Phase III clinical trial for its anti-psychotic candidate, Doria. Environmentally, the company achieved a 10% reduction in CO2 emissions, alongside a 24% decrease in electricity consumption and a 27% decrease in natural gas consumption. On the social front, ROVI expanded its workforce to 1,191 employees, maintaining a strong commitment to gender equality with women representing 56% of the total payroll.
Company: Laboratorios Farmaceuticos Rovi SA
Sector: Manufacturing
Country: Spain
Year: 2017
Type: AR2
Pages: 118
Back to company
Laboratorios Farmaceuticos Rovi SA
Annual Report
The report highlights Laboratorios Farmaceuticos ROVI's financial and ESG performance for the fiscal year 2017, marked by a 4% growth in operating revenue to 275.6 million euros. Key achievements include the international launch of its enoxaparin biosimilar in Germany and the commencement of the Phase III clinical trial for its anti-psychotic candidate, Doria. Environmentally, the company achieved a 10% reduction in CO2 emissions, alongside a 24% decrease in electricity consumption and a 27% decrease in natural gas consumption. On the social front, ROVI expanded its workforce to 1,191 employees, maintaining a strong commitment to gender equality with women representing 56% of the total payroll.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Jan 1, 2017 - Dec 31, 2017
Fiscal Year
2017
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Water Consumption
Women on Board
Women in Management
Employees